Behind The Scenes Of Pharma Mergers And Acquisitions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Behind The Scenes Of Pharma Mergers And Acquisitions


Pharmaceutical Technology Europe
Volume 22, Issue 9


Nathan Jessop
Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009. According to KPMG International, the scale of merger and acquisition activity was the highest since 2004.1 Over the period 2004–2009, the total disclosed value of such deals in the pharma sector reached $226.2 billion.1 Prior to 2005, KPMG had estimated the average size of the deals in the pharma industry at $164 million, but for the period 2005–2009, the average size of the deals increased to $430 million.1 One reason for the sudden increase in value was the spate of 'megamergers' by pharmaceutical companies ranked in the top ten (by sales). Of greatest importance were the deals that saw Pfizer take over Wyeth for $68 billion, Merck & Co. acquire Schering-Plough for $41 billion and Roche taking over Genentech for $46.8 billion.2,3 Another important deal by a major pharmaceutical company, Abbott, was the acquisition of Solvay's pharmaceutical business for around $7 billion.3

It is an open secret that many of the major companies have struggled to increase the output of new drugs, and so mergers and acquisitions serve as a quick means to reinvigorate their pipelines. For example, the megamergers by Pfizer, Merck and Roche were clearly designed to strengthen their R&D abilities in the biotech field, which is seen as the future for drug development. In fact, Roche now openly describes itself as the world's largest biotech company,3 and in 2009 it terminated its membership in the Pharmaceutical Research and Manufacturers Association (PhRMA), to join the Biotech Industry Organization (BIO), a major biotech lobbying force.4 Apart from pipelines, companies also feel that economies of scale can be achieved through combining sales forces and marketing teams.3


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here